Document:

Executive
Employment Agreement

 

This
Executive Employment
Agreement (the
“Agreement”) is made
as of 10/15/14
between Aja
Cannafacturing Inc.
with its principal
place of
business located
at Nevada
(the "Company")
and Kendall A Smith,
located in Las
Vegas, NV (the
"Executive").

 

1.      
Terms
of Employment

 

(a)      
Position. Company
hereby
employs
the Executive
CEO as President,
and the Executive accepts
such employment with
Company subject
to the terms
and conditions
of this
Agreement.

 

(b)      
Duties.
Executive shall
have such duties
and responsibilities as
may be assigned by
the Board of
Directors not inconsistent with
the position.

 

(c)      
Dedication.
Executive shall
devote his
full business
time and
best efforts to
the business
and affairs
of the
Company.

 

(d)      
Performance.
Executive shall
faithfully and
diligently perform
Executive’s duties
in conformity
with the directions of
the Company and
serve the Company
to the best
of Executive’s
abilities.

 

(e)       
Permitted
Activities.
Executive may:

 

(i)           
Serve on
industry, trade, civic
or charitable boards or
committees;

 

(ii)          
Engage
in charitable
activities and community
affairs; and

 

(iii)      
Manage personal
investments, as long
as such activities
do not materially
interfere with
the performance
of Executive's duties
and responsibilities.

 

2.      
Compensation

 

(a)      
Base
Salary

 

(i)                 
Salary.
Executive shall
receive a base salary
in the amount
of $100,000
as a "Base
Salary".

 

(ii)               
Payment. The Base
Salary shall be payable in accordance
with the customary
payroll practices of
the Company.
Contract date recognized
as 10/15/14. Compensation
initiation will
launch based on
the date of
adequate funding.
Therefore, any
compensation not paid on
time would be corrected
through a retro-active
payments.

 

(iii)            
Adjustments. The
Base Salary may
be increased from time
to time
during the term
of this
Agreement in
the sole discretion
of the Company
Board of
Directors.

 

(b)      
Signing
Bonus. Upon
execution of
this Agreement,
Company shall
pay to
Executive an
initial signing bonus
of 1,000,000
shares of
Class A Convertible
Preferred Stock.

 

(c)      
Performance
Bonus. For
each
fiscal year during the
term of
employment, the Executive shall
be eligible to receive
a bonus
in a
range of
10 – 125%
based on performance,
and as may
be determined from
time to
time by the Board
in its discretion
based on increase
of new

business
relationships are
made operational with
transactions and
functioning business
contracts are established.
(Performance scale
TBD)

 

(d)      
Incentive Compensation.
During the
term of
employment, the Executive shall
be eligible to participate
in any equity-based
incentive compensation plan
or program.

 

    	 

    	 

    

 

Preferred
Stock Compensation.
Preferred share
of AJAC
f/k/a IDS
Solar Technologies (IDST)
stock. This
shall become
convertible to
common shares
to a maximum
of 50.1%
of the
issued and outstanding
shares of
stock based
on the date of
signing of
this contract. These
would be granted
to the Executive
in five (5)
equal increments based on
the following
milestones:

 

(i)        
the initial
increment immediately
upon initiation of
this Agreement.

 

(ii)        
the second-third
of the balance
released upon
a business plan
and intellectual
Properties being
defined and
delivered to the company.

 

(iii)      
Final third
of balance
of preferred
stock granted upon
Revenue goals
established and
approved by the
company’s new
board upon
“Change of
Control” going
to Mr. Kendall
A. Smith.

 

3.      
Expenses

 

(a)      
Reimbursement. Company
shall pay
all reasonable travel,
dining and
other ordinary,
necessary and
reasonable business
expenses incurred
by the Executive in the
performance of
his duties
under this Agreement,
subject to budget
and/or other limitations
or conditions imposed
by the Executive
Committee and/or
the Board.

 

(b)      
Substantiation.
The Executive shall,
as a condition of
any such
payment or
reimbursement, submit verification, substantiation
and documentation of
the nature and
amount of
such expenses
in accordance
with the policies
of Company
which is submittal of
an Expense Report
with associated
receipts.

 

4.      
Holiday
& Vacation.

 

(a)      
Entitlement. The
Executive shall be entitled
to 3 weeks
(15 business
days) of
vacation leave
each year during
the term of
this Agreement
without any
deduction in
his compensation,
and at such times
within each year
as the Executive may
determine, taking into account
Company's schedule
and the Executive's
duties relative
thereto, such
vacation leave which
a maximum
of 1
week of
vacation shall be carried
over at the end
of each
year if
not fully
utilized in
that year.

 

(b)      
Vacation
Benefits
upon Termination.
Upon the termination
or expiration
of the Executive's
employment by
Company under
this Agreement,
the Executive shall be entitled
to compensation
for any
unutilized vacation leave.

 

(c)      
Paid
Holidays. 
The Executive
shall be entitled
to 11 (eleven)
recognized Company
Holidays annually
that will be paid
at throughout the duration of
employment agreement.

 

5.      
Benefits.

 

(a)      
Health
& Dental Insurance:
will be offered
to employee based
on company
policy of
50% paid
contribution by company
and 50% by
employee. This
employee becomes
eligible on first
day of
the month
following the completion
of 90 days
of employment.
This will include
Health and
Dental Insurance.

 

(b)      
Term Life
Insurance.
In addition
to any
term life insurance
provided as
an optional purchase
to Executives of
Company, Company
shall purchase a term
life insurance policy
in the amount
of $1,000,000
for personal life
on the life
of the Executive
Kendall A Smith, through
the company’s
deemed Insurance
supplier AIM Professional
Services. Executive would
identify beneficiaries
and the
policy shall
remain in effect
for the duration of
Executive's employment
with Company
under this Agreement.
The obligation of
Company to
purchase such policy
shall be conditioned
on Executive's
successful completion of
any required
medical examination(s) such that
the policy
can be bought at standard
rates. The Executive
shall, in his
sole discretion, name
the beneficiaries of
the policy.

 

(c)      
Key
Man Life
Insurance. The
Company has
the right but not the
obligation for
a term life
insurance policy
for Aja
Cannafacturing as
the beneficiary in
the amount of
$1,000,000 for
personal life on
the life of
the Executive,
through the
company’s deemed
Insurance supplier
AIM Professional
Services. The policy
shall remain in
effect for the
duration of
Executive's employment
with Company under
this Agreement.
The obligation
of Company
to purchase such
policy shall
be conditioned on Executive's
successful completion of
any required
medical examination(s)
such that
the policy
can be bought at standard
rates. The Executive
shall, in
his, name
the company as
sole beneficiary
of the policy.

 

6.      
Representations and
Warranties. The Company
and the Executive respectively
represents and
warrants to
each other
that each respectively
is fully
authorized and empowered
to enter
into the
Agreement and that
their entering into
the Agreement and
to each parties'
knowledge the performance
of their respective obligations
under the Agreement
will not violate
any agreement
between the Company
or the Executive respectively
and any other
person, firm or
organization or any
law or
governmental regulation.

 

    	2

    	 

    

 

7.      
Confidential
Information

 

(a)      
Obligation. The
Executive agrees to
maintain the
strict confidentiality of
all Confidential
Information during the
term of
this Agreement
and thereafter.

 

(b)      
Scope.
For purposes
of this
Agreement, "Confidential
Information" shall mean
all information and
materials of
Company, and
all information
and materials
received by Company
from third parties
(including but not limited
to affiliates, subsidiaries,
chapters, and
members of
Company), which are not generally
publicly available
and all other information
and materials
which are of
a proprietary
or confidential nature,
even if
they are not
marked as such.

 

(c)      
Survival. This
provision shall
survive the termination of
this Agreement
indefinitely.

 

8.      
Intellectual Property

 

(a)      
Ownership. Executive
agrees that 
all copyrights, trademarks,
patents, and other intellectual
property rights
to works
or marks arising
in from
or in connection
with the Executive's
employment by
Company are
"work made
for hire" within
the definition of
Section 101 of the
Copyright Act
(17 U.S.C. 101) and shall
remain the
sole and exclusive property
of Company.

 

(b)        
Consulting
engagements
for executive,
in any
correlation to an
Aja Cannafacturing
market, products or
intellectual expertise would need
to be performed
as part of
Aja Cannafacturing Inc.,
or an
AJAC wholly
owned subsidiary.

 

(c)      
Assignment of
Interest.
To the extent any
work product is
not deemed
to be a work
made for
hire within the definition of
the Copyright Act,
Executive with
effect from
creation of
any and
all work
product, hereby
assigns, and
agrees to assign,
to Company all
right, title and interest
in and to
such work
product, including but
not limited
to copyright, all rights
subsumed thereunder,
and all other intellectual
property rights,
including all extensions
and renewals
thereof.

 

(d)      
Moral Rights.
Executive also
agrees to
waive any
and all moral
rights relating to
the work
product, including
but not
limited to,
any and
all rights
of identification
of authorship
and any
and all
rights of
approval, restriction
or limitation on use,
and subsequent
modifications.

 

(e)       
Assistance.
Executive further
agrees
to provide all
assistance reasonably
requested by Company,
both during
and subsequent to
the Term
of this
Agreement, in the
establishment, preservation
and enforcement of
Company's rights
in the work
product.

 

(f)       
Return
of
Property.
Upon the
termination of
this Agreement,
Executive agrees
to deliver promptly
to Company all
printed, electronic, audio-visual,
and other tangible manifestations
of work
product, including
all originals
and copies
thereof.

 

9.      
Non-Competition

 

(a)      
Restrictions. During
the term
of this
Agreement and
for a period
of 2 Years
of direct
competition immediately
following the
termination of
this Agreement,
Executive shall not,
directly or indirectly,
without the prior
written consent
Company, own,
manage, operate, join, control, finance
or participate in
the ownership,
management, operation, control or financing
of, or
be connected as
an officer, director,
employee, partner,
principal, agent, representative,
or consultant
of any
Entity engaged
in the Restricted
Business of
industrial hemp, or medicinal
marijuana, development, production or
sales in to these
markets Solar.

 

(b)      
Exceptions.
Executive shall
not be deemed
to be in contravention
of the
foregoing if
Employee participates
as a passive investor
holding up
to 1% of
the equity
securities of
an Entity engaged
in the Restricted
Business, which
securities are publicly
traded.

 

    	3

    	 

    

 

10.      
Non-Solicitation.

During
the term of
this Agreement
and for
a one
year period
after any termination
of this
Agreement, Executive
will not,
without the prior
written consent of
the Company,
either directly
or indirectly,
on Executive
's own behalf
or in the
service or on behalf
of others,
solicit or
attempt to solicit,
divert or
hire away any
person employed by
the Company.

 

11.      
Non-Disparagement.

 

(a)      
Executive
Obligation.
Executive
will not
at any time,
during or
after the
Term, disparage, defame
or denigrate the
reputation, character,
image, products
or services
of the
Company, or of
any of
its Affiliates,
or, any of
its or
its Affiliate
s directors,
officers, stockholders, members, employees
or agents.

 

(b)      
Company
Obligation.
The Company
will not, except
as may be
required by law,
issue any
official press release
or statement which is intended
to disparage
Executive.

 

12.       
Acknowledgement.

 

Executive
expressly acknowledges that
the covenants
of this
Agreement are supported
by good and
adequate consideration,
and that
such covenants
are reasonable
and necessary in terms
of duration,
scope and
geographic area to
protect the legitimate
business interests
of Company.

 

13.      
Term
of Employment

 

(a)      
Initial Term.
The term
of the Executive's
employment under
this Agreement shall commence
on the Effective Date
and continue until
8/31/15 (the "Term"), unless
his employment
is sooner
terminated pursuant
to the provisions
of the
Termination of
Employment section.

 

(b)       
Automatic
Renewal.
Commencing
on 9/1/15
and on each
anniversary of
that date
thereafter, the Term
shall be extended
for an additional one year
period.

 

(c)       
Notice
Not to
Renew. Either
party may give
notice of
the intention not
to extend the
Term in
writing at
least 120 days
prior to each such
anniversary date.

 

14.      
Termination
of Employment

 

(a)      
Termination Upon
Death. This
Agreement shall terminate
automatically upon
the death of
the Executive.

 

(b)       
Automatic
Termination Upon
Disability.
This Agreement
shall terminate automatically
upon Total Disability
of the Executive.

 

Total
Disability.
Total Disability means
the Executive is unable to perform
the duties set forth in
this Agreement
for a period of
twelve consecutive
weeks, or 90 cumulative
business days
in any 12-month
period, as
a result
of physical
or mental illness or
loss of
legal capacity.

 

    	4

    	 

    

 

(c)       
Termination Upon
Retirement. The
Executive may voluntarily
terminate this
Agreement at
any time
by reason
of Retirement.

 

Retirement.
Retirement is the
cessation by
Executive of all
full-time employment
of any
kind.

 

(d)       
Termination by
the Company
For Cause.
The Company
shall have the
right to terminate
Executive's employment
under this Agreement
at any
time for
Cause, which termination shall
be effective immediately.
Termination for
"Cause" shall include
termination for:

(i)                 
material breach
of this
Agreement by
Executive;

 

(ii)             
intentional nonperformance
or mis-performance of
such duties,
or refusal to abide
by or comply
with the reasonable
directives of
his superior
officers, or the
Corporation's policies
and procedures;

 

(iii)           
Executive's
gross
negligence in
the performance of
his material
duties under this
Agreement;

 

(iv)           
Executive's
willful dishonesty, fraud
or misconduct
with respect to
the business
or affairs
of the Corporation,
that in the reasonable judgment
of the
President and/or
the Board of
Directors materially and
adversely affects
the Corporation;

 

(v)               
Executive's
conviction of,
or a
plea of
nolo contendere
to, a
Class I
or II
felony or other
crime involving;

 

(vi)           
the commission of
any act
in direct
or indirect competition with
or materially
detrimental to
the best interests
of Corporation
that is
in breach
of Executive s
fiduciary duties of
care, loyalty and
good faith
to Corporation.

 

Cause
will not,
however, include any
actions or circumstances
constituting Cause under
(i) or (ii) above
if Executive cures
such actions or
circumstances within 30 days
of receipt
of written
notice from
Corporation setting
forth the
actions or
circumstances constituting
Cause. In the
event Executive's
employment under
this Agreement is
terminated for
Cause, Executive shall
thereafter have
no right to receive
compensation or
other benefits under
this Agreement.

 

Exception
to be expenses
and any earned
income up to
that point in time.

 

(e)       
Termination by
the Company
Without Cause.
The Company
may upon a
majority vote
of the Board
of Directors, terminate
the Executive's
employment under
this Agreement
without Cause
at any time
upon 120
days prior
written notice to
the Executive. 
Executive shall be
entitled to Severance
Benefits as
stated in
the Termination Benefits
section.

 

(f)      
Termination
Upon a
Change in Control.
If the Executive's
employment is
terminated by
the Company
without Cause
or by the Executive
for Good
Reason in connection
with or within
two years
after Change
in Control, the
Executive shall be entitled
to Severance
Benefits as
stated in
the Termination
Benefits section.

 

(g)       
Change
in Control.
For
purposes of
this Agreement,
unless the
Board determines
otherwise, a Change
of Control of
the Company shall
be deemed to
have occurred at
such time
as:

 

(i)                 
any
person
(as the term
is used
in Sections
13(d) and
14(d) of
the Securities Exchange
Act of
1934, as
amended (the
Exchange Act)) is
or becomes the
beneficial

owner
(as defined in
Rule 13d-3 under
the Exchange
Act), directly or
indirectly, of
voting securities
of the Company
representing more
than 50%
of the
Company s
outstanding voting
securities or
rights to acquire
such securities
except for any
voting securities
issued or purchased
under any
employee benefit plan of
the Company or
its subsidiaries;
or

 

(ii)               
any
sale,
lease,
exchange
or other transfer (in one
transaction or
a series
of transactions)
of all
or substantially all
of the assets
of the Company;
or

 

(iii)            
a plan of
liquidation of
the Company
or an agreement for
the sale or
liquidation of
the Company is
approved and completed;
or

 

(iv)             
the Board determines
in its sole discretion
that a
Change in Control
has occurred,
whether or
not any
event described
above has occurred
or is contemplated.

 

    	5

    	 

    

 

(h)       
Termination by
the Executive for
Good Reason. 
The Executive may
terminate his
employment under
this Agreement
for Good Reason,
in which case
the Executive shall be
entitled to Severance
Benefits as
stated in
the Termination Benefits
section. For
purposes of
this Agreement,
"Good Reason" shall
mean the
occurrence of
any of
the following
events without
the Executive's written
consent:

 

(i)                 
a material
diminution of
the Executive's
title, authority,
status, duties or responsibilities;

 

(ii)               
any
reduction in
the Executive's
Base Salary;

 

(iii)            
a material breach
by the Company
of this Agreement;
or

 

(iv)             
the Company
requires Executive to locate
his office
to a location
more than fifty
miles outside
of the metropolitan
area of the
Executive's home
city.

 

(i)      
Termination
by the Executive
Without Good Reason.
The Executive may
terminate his
employment under
this Agreement
at any
time for
any reason
or no
reason by
giving the
Company 30 days
prior written
notice of
the termination.
Following any
such notice, the Company
may reduce
or remove any and
all of
Executive s duties,
positions and
titles with the
Company, and any such
reduction or
removal shall not constitute
Good Reason.

 

(j)      
Notice Requirements.
Any
Termination by
the Company
for Cause,
or by
Executive for Good Reason,
shall be communicated by Notice
of Termination
to the other
party hereto
given in
accordance with the Notice
section of
this Agreement.
For purposes
of this
Agreement, a "Notice
of Termination" means a
written notice which:

 

(i)                 
indicates
the specific
termination provision in
this Agreement
relied upon,

 

(ii)               
to the extent
applicable, sets
forth in reasonable
detail the facts
and circumstances
claimed to provide
a basis for
termination of Executive's
employment under the provision
so indicated and

 

(iii)            
if the
Date of
Termination (as defined
below) is
other than the date
of receipt of
such notice, specifies
the termination
date.

 

The failure
by Executive or the Company
to set forth
in the Notice
of Termination any
fact or
circumstance which contributes
to a showing
of Good Reason
or Cause
shall not
waive any right
of Executive
or the Company,
respectively, hereunder
or preclude Executive or
the Company,
respectively, from
asserting such
fact or circumstance
in enforcing
Executive's or
the Company's
rights hereunder.

 

(k)      
Date of
Termination. "Date
of Termination" means:

 

(i)                 
if the
Executive's employment
is Terminated
by the Company
for Cause,
or by
the Executive for
Good Reason, the date
of receipt of
the Notice of
Termination or any later
date specified
therein, as the
case may be,

 

(ii)               
if the
Executive's employment
is terminated
by the Company
other than for
Cause or
Disability, the Date
of Termination
shall be the
date on which the Company
notifies the Executive
of such
termination and

 

(iii)            
if the
Executive's employment
is terminated
by reason of
death, Retirement
or Disability,
the Date of
Termination shall be
the date of
death or
Retirement of
the Executive or
the Disability Effective Date,
as the case
may be.

 

(l)      
Release.
Notwithstanding
anything
in the
Severance Benefits
section to
the contrary, in no
event shall
the Executive be entitled
to receive any
amounts, rights or
benefits under the
Severance Benefits
section unless
the Executive executes a
release of claims
against the Company.

 

    	6

    	 

    

 

15.      
Compensation
Upon Termination

 

(a)      
Accrued Obligations.
"Accrued
Obligations" shall mean, as
of the
Date of
Termination, the sum of:

 

(i)                 
the Executive's
base salary under this
Agreement through the Date
of Termination
to the extent not
theretofore paid,

(ii)               
the amount
of any
deferred compensation and
other cash
compensation accrued
by the Executive as
of the
Date of
Termination to the extent
not theretofore paid,

 

(iii)            
any
vacation pay,
expense reimbursements
and other
cash entitlements
accrued by
the Executive as of
the Date of
Termination to the extent
not theretofore paid,

 

(iv)             
any
grants
and awards
vested or
accrued under any
equity-based incentive
compensation plan or
program and

 

(v)               
all other
benefits which have
accrued as of
the Date of
Termination. For the
purpose of
this definition, except
as provided
in the applicable
plan, program
or policy,
amounts shall be deemed to
accrue ratably
over the
period during which
they are
earned, but no discretionary compensation
shall be deemed
earned or
accrued until it
is specifically
approved by the Board
in accordance
with the applicable
plan, program or
policy.

 

With
respect to the provision
of Other
Benefits, the term Other Benefits as
utilized in this
Section shall
include, without
limitation, and Executive shall
be entitled after
the Disability Effective Date
to receive.

 

(b)         
Severance Benefits.
"Severance
Benefits" shall mean,
as of the Date
of Termination, an amount
equal to the sum
of (i)
six (6)
months of the
Executive's then-current
annual base salary.

 

(c)       
Additional
Compensation. Reimbursement
of any
and all
expenses accrued up
to that
separation date.

 

(d)       
Cause;
Without Good Reason.
If the Executive's
employment is terminated
By the
Company For
Cause or
By the Executive
Without Good Reason
during the Employment
Period, the Company
shall provide to
the Executive the Accrued
Obligations, and shall
have no other severance
obligations under
this agreement. In
such case,
all Accrued
Obligations shall
be paid to
the Executive in a lump sum
in cash within 30 days
of the Date
of Termination.

 

(e)       
Without Cause; With
Good Reason.
If the Executive's
employment is
terminated By
the Company
Without Cause or
By the Executive
With Good Reason during
the Employment
Period, the Company
shall provide to the
Executive the Accrued
Obligations and
the Severance
Benefits as
described above. 
In such case,
all Accrued
Obligations shall
be paid to
the Executive in a lump
sum in cash within
30 days
of the
Date of
Termination and all Severance
Benefits shall
be payable in substantially
equal monthly
installments for
a period of
12 months (the
"Severance Period") in
accordance with the
Company's regular
payroll practices.

 

(f)     
Death,
Disability
or Retirement.
If Executive
s employment
is terminated
by reason
of Executive’s
death, Disability or
Retirement, the Company
shall pay
to the
Executive (or the Executive’s
estate or beneficiaries) the Accrued
Obligations. In such
case, all
Accrued Obligations
shall be paid
to the Executive
in a lump sum in cash
within 30 days of
Executive’s death,
Disability or Retirement.

 

(g)       
Nature
of Payments.
Any
amounts
due under
this Section
are in the
nature of
severance payments
considered to
be reasonable by the Company
and are not
in the
nature of
a penalty.

 

16.      
Indemnification.
The Company
shall indemnify
the Executive,
to the maximum
extent permitted
by applicable law
and by its
certificate of
incorporation, against
all costs, charges and expenses
incurred or
sustained by the Executive in connection
with any action,
suit or
proceeding to which he
may be made
a party
by reason of
being an officer, director
or employee
of the Company
or of
any subsidiary or
affiliate of
the Company
or any other
corporation for
which the Executive serves
in good faith
as an officer, director,
or employee
at the Company's
request.

 

    	7

    	 

    

 

17.      
General
Provisions

 

(a)      
Entire
Agreement.
This Agreement
constitutes the
entire agreement
between the parties, and supersedes
all prior agreements, representations
and understandings
of the parties,
written or
oral.

 

(b)       
Counterparts.
This
Agreement may
be executed in counterparts,
each of which
shall be deemed
to be an original,
but all
of which,
taken together,
shall constitute
one and the same
agreement.

 

(c)       
Amendment.
This Agreement
may be amended
only by written
agreement of
the parties.

 

(d)       
Notices.
All notices
permitted or
required under this
Agreement shall be in writing
and shall
be delivered in person or
mailed by first class, registered
or certified
mail, postage prepaid, to
the address of
the party
specified in this
Agreement or
such other address
as either party may
specify in
writing. Such notice shall
be deemed to
have been given upon
receipt.

 

(e)       
Assignment.
This
Agreement
shall not
be assigned by
either party
without the consent of
the other party.

 

(f)      
Governing Law.
This
Agreement shall be
governed by and
construed in accordance
with the laws
of the State
of California,
without regard to
its conflict of
laws rules.

 

(g)       
No
Waiver
of Rights.
A failure
or delay
in exercising any
right, power
or privilege
in respect
of this
Agreement will
not be presumed
to operate as
a waiver,
and a single
or partial exercise
of any
right, power or
privilege will not
be presumed to preclude
any subsequent
or further
exercise, of
that right, power
or privilege or
the exercise of
any other
right, power or privilege.

 

 

Aja Cannafacturing
Inc.

 

 

By:
/s/ Scott Plantinga  

Print
name: Scott Plantinga

Title:
CEO

 

  

/s/ Kendall A. Smith 

Kendall
A. Smith

 

    	8Exhibit 4.10

 

WARRANT AGENT AGREEMENT

 

This Warrant Agent Agreement (this “Agreement”)
is made as of October ___, 2014 between Palatin Technologies, Inc., a Delaware corporation (“Company”), and
American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (“Warrant Agent”).

 

WHEREAS, the Company is engaged in a public
offering (“ Offering ”) of shares of the Company’s common stock, par value $0.01 per share (“ Common
Stock ”) and Common Stock Purchase Warrants (“Warrants”), evidencing the right of the holders thereof
(each, a “ Holder ”) to purchase up to an aggregate of ___________ shares of Common Stock (the “ Warrant
Shares ”) for $0.__ per share, subject to adjustment as described herein; and

 

WHEREAS,
the Company has filed with the Securities and Exchange Commission a Registration Statement on Form S-1 (File No. 333-
198992) (“Registration Statement”) covering the registration
under the Securities Act of 1933, as amended (“ Act ”), of, among other securities, the Warrants and the Warrant
Shares; and

 

WHEREAS, the Company desires the Warrant
Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration,
transfer, exchange, replacement and exercise of the Warrants and, in the Warrant Agent’s capacity as the Company’s
transfer agent, deliver the Warrant Shares; and

 

WHEREAS, the Company desires to provide
for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights,
limitation of rights, and immunities of the Company, the Warrant Agent, and the Holders; and

 

WHEREAS, all acts and things have been done
and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf
of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution
and delivery of this Agreement.

 

NOW, THEREFORE, in consideration of the
mutual agreements herein contained, the parties hereto agree as follows:

 

1.             CERTAIN
DEFINITIONS.

 

“Affiliate” means any
Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Common Stock Equivalents”
means any securities of the Company that would entitle the Holder to acquire at any time Common Stock, including, without limitation,
any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable
for, or otherwise entitles the Holder to receive, Common Stock.

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person” means an individual
or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint
stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Trading Day” means a day on which the
Common Stock is traded on a Trading Market

 

 

    	1

    	 

    

 

“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or
quoted for trading on the date in question: the NYSE MKT LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global
Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing).

 

“VWAP” means, for any
date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted
on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTC Bulletin Board is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board,
(c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock
are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

“Warrant Certificate”
means a certificate in substantially the form attached as Exhibit A representing such number of Warrants and Warrant Shares
as is indicated on the face thereof, provided that any reference to the delivery of a Warrant Certificate in this Agreement shall
include delivery of a notice from the Depository or a Participant (each as defined below) of the transfer or exercise of Warrants
in the form of a Book-Entry Warrant Certificate (as defined below).

 

 2.              APPOINTMENT
OF WARRANT AGENT. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant
Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this
Agreement.

 

3.             WARRANTS.

 

3.1              BOOK-ENTRY
WARRANT CERTIFICATES. The Warrants shall initially be issuable in book-entry registration only and evidenced by a global Warrant
Certificate (the “ Book-Entry Warrant Certificates ”). All of the Warrants shall initially be represented by
one or more Book-Entry Warrant Certificates deposited with the Depository Trust Company (“Depository”) and registered
in the name of Cede & Co., a nominee of the Depository. Ownership of beneficial interests in the Warrants shall be shown
on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depository or its nominee
for each Book-Entry Warrant Certificate or (ii) institutions that have accounts with the Depository (such institution, with
respect to a Warrant in its account, a “Participant”). If the Depository subsequently ceases to make its book-entry
settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding other arrangements for book-entry
settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in,
book-entry form, the Warrant Agent shall provide written instructions to the Depository to deliver to the Warrant Agent for cancellation
each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to each Holder a Warrant Certificate.

 

3.2              EFFECT
OF COUNTERSIGNATURE. The Warrant Certificates shall be executed on behalf of the Company by its Chief Executive Officer or
Chief Financial Officer, either manually or by facsimile signature, and the Warrant Certificates shall be countersigned by the
Warrant Agent either manually or facsimile signature and shall not be valid for any purpose unless so countersigned. In case any
officer of the Company who shall have signed any of the Warrant Certificates shall cease to be such officer of the Company before
countersignature by the Warrant Agent and issuance and delivery by the Company, such Warrant Certificates, nevertheless, may be
countersigned by the Warrant Agent, issued and delivered with the same force and effect as though the person who signed such Warrant
Certificate had not ceased to be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company
by any person who, at the actual date of the execution of such Warrant Certificate, shall be a proper officer of the Company to
sign such Warrant Certificate, although at the date of the execution of this Agreement any such person was not such an officer.

 

    	2

    	 

    

 

3.3.         REGISTRATION.

 

3.3.1              WARRANT
REGISTER. The Warrant Agent shall maintain books (“Warrant Register”) for the registration of original issuance
and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and
register the Warrants in the names of the respective Holders thereof in such denominations and otherwise in accordance with instructions
delivered to the Warrant Agent by the Company.

 

3.3.2              REGISTERED
HOLDER. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the person in whose name such Warrant shall be registered upon the Warrant Register (“ registered holder ”),
as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other
writing on the Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise
thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

4.            TERMS
AND EXERCISE OF WARRANTS

 

4.1           WARRANT
PRICE. Each Warrant shall, when countersigned by the Warrant Agent, entitle the registered Holder, subject to the provisions
of such Warrant and of this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the
price of $0.__ per whole share, subject to the adjustments provided in Section 5 hereof and in the last sentence of this Section 4.1.
The term “Exercise Price” as used in this Agreement refers to the price per share at which Common Stock may
be purchased at the time a Warrant is exercised. The Company in its sole discretion may lower the Exercise Price at any time prior
to the Expiration Date.

 

4.2           DURATION
OF WARRANTS. A Warrant may be exercised only during the period (“Exercise Period”) commencing on the date
of issuance, which is expected to occur on October __, 2014 (“Initial Exercise Date”), and terminating at 5:00
p.m., New York City time on the five (5) year anniversary of the Initial Exercise Date (“Expiration Date”).
Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect
thereof under this Agreement shall cease at the close of business on the Expiration Date. The Company in its sole discretion may
extend the duration of the Warrants by delaying the Expiration Date.

 

4.3          EXERCISE
OF WARRANTS.

 

4.3.1              EXERCISE
OF WARRANT. Exercise of the purchase rights represented by the Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Expiration Date by delivery to the Company (or such other office or
agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing
on the books of the Company) of a duly executed e-mailed copy of the Notice of Exercise form annexed hereto, subject to the Company’s
confirmation of receipt of the e-mail. Within three (3) Trading Days following the date of exercise as aforesaid, the Holder
shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer of immediately
available funds, or pursuant to the cashless exercise procedure specified in Section 2(c) below, if such cashless exercise
procedure is available and is specified in the applicable Notice of Exercise. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender the Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender the Warrant to
the Company for cancellation within three (3) Trading Days after the date the final Notice of Exercise is delivered to the
Company. Partial exercises of the Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder
shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased
and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one (1) Business
Day after receipt of such notice.

 

    	3

    	 

    

 

4.3.2       CASHLESS
EXERCISE. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holders, then the Warrants may only be exercised, in whole
or in part, at such time by means of a “cashless exercise” in which the Holders shall be entitled to receive that number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A) = the VWAP on the Trading Day immediately preceding
the date on which a Holder elects to exercise the Warrant by means of a “cashless exercise,” as set forth in the applicable
Exercise Notice;

 

(B) = the Exercise Price of the Warrant, as adjusted
hereunder; and

 

(X) = the number of Warrant Shares that would be issuable
upon exercise of such Warrant in accordance with the terms of the Warrant if such exercise were by means of a cash exercise rather
than a cashless exercise.

 

Upon receipt of an Exercise Notice for a cashless exercise,
the Warrant Agent will promptly deliver a copy of the Exercise Notice to the Company to confirm the number of Warrant Shares issuable
in connection with the cashless exercise. The Company shall calculate and transmit to the Warrant Agent, and the Warrant Agent
shall have no obligation under this section to calculate, the number of Warrant Shares issuable in connection with the cashless
exercise.

 

4.3.3              DELIVERY
OF WARRANT SHARES UPON EXERCISE. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder
by crediting the account of the Holder’s prime broker with The Depository Trust Company through its system (“DWAC”)
system if the Company is then a participant in such system and either (A) there is an effective registration statement permitting
the issuance of the Warrant Shares to the Holder or (B) the Warrant is being exercised via cashless exercise, and otherwise
by physical delivery to the address specified by the Holder in the Notice of Exercise, in each case by the date that is three (3) Trading
Days after the latest of (A) the delivery to the Company of the Notice of Exercise and receipt of the DWAC request from the
Holder’s prime broker (if applicable), (B) surrender of the Warrant (if required) and (C) payment of the aggregate
Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the “ Warrant Share Delivery
Date ”). The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to
be named therein shall be deemed to have become the holder of record of such shares for all purposes, as of the date the Warrant
has been properly exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all
taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having
been paid.

 

4.3.4              DELIVERY
OF NEW WARRANTS UPON EXERCISE. If a Warrant shall have been exercised in part, the Company shall, at the request of the Holder
and upon surrender of the Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver
to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by the Warrant,
which new Warrant shall in all other respects be identical to the Warrant.

 

    	4

    	 

    

 

4.3.5              RESCISSION
RIGHTS. If the Company fails to cause the Transfer Agent to transmit either to the Holder’s prime broker the Warrant
Shares or to the Holder a certificate or the certificates representing the Warrant Shares, as applicable pursuant to Section 2(d)(i)
hereof by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

4.3.6              COMPENSATION
FOR BUY-IN ON FAILURE TO TIMELY DELIVER SHARES UPON EXERCISE. In addition to any other rights available to the Holder, if the
Company fails to instruct the Transfer Agent to transmit to the Holder’s prime broker the Warrant Shares, or to the Holder
a certificate or the certificates representing the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the
Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company
shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at
issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the
option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common
Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example,
if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise
of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In and evidence of the amount of such loss. Nothing
herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely
deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof

 

    	5

    	 

    

 

4.3.7              HOLDER’S
EXERCISE LIMITATIONS. The Company shall not effect any exercise of the Warrant, and the Holder shall not have the right to
exercise any portion of the Warrant, pursuant to Section 4 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates) would beneficially own in
excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares
of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable
upon exercise of the Warrant with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of the Warrant beneficially
owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of
any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation
on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except
as set forth in the preceding sentence, for purposes of this Section 4.3.7, beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the
Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 4.3.7 applies, the determination of whether the Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of the Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether the Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of
which portion of the Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and neither the Company
nor the Warrant Agent shall have any obligation to verify or confirm the accuracy of such determination and shall have no liability
for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination
as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder. For purposes of this Section 4.3.7, in determining the number of outstanding
shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement
by the Company or (C) a more recent written notice by the Company or the Warrant Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of the Holder, the Company shall within two (2) Trading Days
confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including the Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of
Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.98% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of the Warrant.
Upon delivery of a written notice to the Company, the Holder may from time
to time increase (with such increase not effective until the sixty-first (61st) day after delivery of such notice) or
decrease the Beneficial Ownership Limitation to any other percentage not in excess of 19.99% (except that such increased percentage
may exceed 19.99% in the event that (a) the Company obtains the approval of its stockholders as required by the applicable rules
of the Trading Market on which the Common Stock is traded for issuances of shares of Common Stock in excess of such amount or (b)
the Company is not subject to rules of a Trading Market limiting issuances of shares of Common Stock in excess of such amount)
as specified in such notice; provided that (i) any such increase in the Beneficial Ownership Limitation will not be effective until
the sixty-first (61st) day after such notice is delivered to the Company, and (ii) any such increase or decrease will
apply only to the Holder and its affiliates and not to any other holder of the Warrant that is not an affiliate of such Holder.
For purposes of clarity, the shares of Common Stock underlying this Warrant in excess of the Beneficial Ownership Limitation shall
not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1)
of the Exchange Act. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 4.3.7 to the extent necessary to correct this paragraph or any portion of this paragraph which may
be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 4.3.7 or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitation as contained in this paragraph
may not be waived and shall apply to a successor holder of the Warrant.

 

4.3.8              VALID
ISSUANCE. All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be
validly issued, fully paid and non-assessable.

 

4.3.9              DATE
OF ISSUANCE. Each person in whose name any such certificate for shares of Common Stock is issued shall for all purposes be
deemed to have become the holder of record of such shares on the date on which the Warrant was surrendered and payment of the Exercise
Price was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and payment
is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such
shares at the close of business on the next succeeding date on which the stock transfer books are open.

 

    	6

    	 

    

 

5.            ADJUSTMENTS.

 

5.1              STOCK
DIVIDENDS AND SPLITS. If the Company, at any time while a Warrant is outstanding: (i) pays a dividend or otherwise makes
a distribution or distributions, in each case payable in shares of its Common Stock, to all holders of Common Stock (and not to
the Holders) (excluding, for avoidance of doubt, any shares of Common Stock issued by the Company upon exercise of the Warrant),
(ii) subdivides outstanding shares of Common Stock into a larger number of shares, or (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then in each case the Exercise Price
shall be multiplied by a fraction, of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding at 5:00 p.m. (New York City time) on the Trading Day immediately before such event, and of which the denominator
shall be the number of shares of Common Stock that would be outstanding immediately after, and solely as a result of, such event,
and the number of shares issuable upon exercise of the Warrant shall be proportionately adjusted such that the aggregate Exercise
Price of the Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately
prior to 9:00 a.m. (New York city time) on the Ex-Dividend Date for such dividend or distribution or the effective date of such
subdivision or combination, as the case may be. “Ex-Dividend Date” means, when used with respect to any dividend,
distribution or issuance, the first date on which the share of Common Stock trade on the Trading Market, regular way, without the
right to receive the relevant dividend, distribution or issuance.

 

5.2              SUBSEQUENT
RIGHTS OFFERINGS. In addition to any adjustments pursuant to Section 5.1 above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of the Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase
Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation).

 

5.3              PRO
RATA DISTRIBUTIONS. If the Company, at any time while a Warrant is outstanding, shall distribute to all holders of Common Stock
(and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe
for or purchase any security other than the Common Stock, then in each such case the Exercise Price shall be adjusted by multiplying
the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such
distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of
which the numerator shall be such VWAP on such record date less the then per share fair market value at such record date of the
portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined
by the Board of Directors in good faith. In each case the adjustments shall be described in a statement provided to the Holder
of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common
Stock. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record
date mentioned above.

 

    	7

    	 

    

 

5.4              FUNDAMENTAL
TRANSACTION. If, at any time while the Warrant is outstanding, (i) the Company, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Company with or into another Person and the Company is not the
surviving corporation, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) the Company,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of
the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged
for other securities, cash or property, or (iv) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group of Persons acquires
more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other
Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise
of the Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of the Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the “ Alternate Consideration
”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which the
Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 4.3.7
on the exercise of the Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share
of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of
Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the
Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of the Warrant following
such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction that is (1) an
all cash transaction, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act, or (3) a
Fundamental Transaction involving a person or entity not traded on a national securities exchange, including, but not limited to,
the NYSE MKT LLC, the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market, the Company or any Successor
Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after,
the consummation of the Fundamental Transaction, purchase this Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental
Transaction. “Black Scholes Value” means the value of the Warrant based on the Black and Scholes Option Pricing
Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as of the day
of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable
Fundamental Transaction and the Expiration Date, (B) an expected volatility equal to the greater of 100% and the average of
10, 20 and 30-day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public
announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall
be the greater of (i) the weighted average price of the Common Stock for the Trading Day immediately preceding the date of announcement
of the applicable  Fundamental Transaction, (ii) the weighted average price of the Common Stock for the Trading Day immediately
following the date of announcement of the applicable  Fundamental Transaction and (iii) the weighted average price of the
Common Stock for the Trading Day immediately preceding the date of consummation of the applicable  Fundamental Transaction,
and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Expiration Date. The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the “ Successor Entity ”) to assume in writing all of the obligations of the Company under
the Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written
agreements and shall, at the option of the Holder, deliver to the Holder in exchange for the Warrant a security of the Successor
Entity evidenced by a written instrument substantially similar in form and substance to the Warrant which is exercisable for a
corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of the Warrant (without regard to any limitations on the exercise of the Warrant)
prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose
of protecting the economic value of the Warrant immediately prior to the consummation of such Fundamental Transaction), and which
is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of the Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under the
Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

 

    	8

    	 

    

 

5.5              CALCULATIONS.
All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may
be. For purposes of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

5.6              NOTICES
OF CHANGES IN WARRANT. Upon every adjustment of the Exercise Price or the number of shares issuable upon exercise of a Warrant,
the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from
such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a
Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon
the occurrence of any event specified in this Section 5, then, in any such event, the Company shall give written notice to
the Warrant Holder, at the last address set forth for such Holder in the warrant register, of the record date or the effective
date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

 

5.7              NO
FRACTIONAL SHARES. Notwithstanding any provision contained in the Agreement to the contrary, no fractional shares or scrip
representing fractional shares shall be issued upon the exercise of Warrants. As to any fraction of a share which the Holder would
otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect
of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

5.8              FORM
OF WARRANT. The form of Warrant need not be changed because of any adjustment pursuant to this Section 5, and Warrants
issued after such adjustment may state the same Exercise Price and the same number of shares as is stated in the Warrants initially
issued pursuant to this Agreement. However, the Company may at any time in its sole discretion make any change in the form of Warrant
that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned,
whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.

 

    	9

    	 

    

 

5.9              NOTICE
OF CERTAIN TRANSACTIONS. If during the term in which the Warrants may be exercised by the Holder (A) the Company shall
declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special
nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders
of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class, (D) the approval
of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any
compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company
shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each
case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the
Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the
date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record
is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail
such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be
specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously disclose such information in compliance with
applicable securities laws. The Holder shall remain entitled to exercise the Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

6.            TRANSFER
AND EXCHANGE OF WARRANTS.

 

6.1              REGISTRATION
OF TRANSFER. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the Warrant
Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by
appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants
shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled shall be delivered by the
Warrant Agent to the Company from time to time upon request.

 

6.2              PROCEDURE
FOR SURRENDER OF WARRANTS. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or
transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the registered
Holder so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event that a Warrant
surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and issue new Warrants in
exchange therefor until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be
made and indicating whether the new Warrants must also bear a restrictive legend.

 

6.3              FRACTIONAL
WARRANTS. The Warrant Agent shall not be required to effect any registration of transfer or exchange which will result in the
issuance of a Warrant Certificate for a fraction of a Warrant.

 

6.4              SERVICE
CHARGES. No service charge shall be made for any exchange or registration of transfer of Warrants.

 

6.5              WARRANT
EXECUTION AND COUNTERSIGNATURE. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the
terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company,
whenever required by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for
such purpose.

 

    	10

    	 

    

 

7.            OTHER
PROVISIONS RELATING TO RIGHTS OF HOLDERS OF WARRANTS.

 

7.1          NO
RIGHTS AS STOCKHOLDER. A Warrant does not entitle the registered Holder to any of the rights of a stockholder of the Company,
including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or
to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of the
Company or any other matter.

 

7.2          LOST,
STOLEN, MUTILATED, OR DESTROYED WARRANTS. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant
Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen,
mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not
the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

 

7.3          RESERVATION
OF COMMON STOCK. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of
Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 

7.4          REGISTRATION
OF COMMON STOCK. The Company will use its best efforts to maintain the effectiveness of the Registration Statement until the
expiration of the Warrants in accordance with the provisions of this Agreement; provided, however, that in no event shall
the Holders have the right to net settle the Warrants for cash irrespective of whether an effective registration statement is then
in effect.

 

8.            CONCERNING
THE WARRANT AGENT AND OTHER MATTERS.

 

8.1          PAYMENT
OF TAXES. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the
Warrant Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of Warrants, but the Company shall
not be obligated to pay any transfer taxes in respect of the Warrants or such shares.

 

8.2          RESIGNATION,
CONSOLIDATION, OR MERGER OF WARRANT AGENT.

 

8.2.1              APPOINTMENT
OF SUCCESSOR WARRANT AGENT. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If
the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing
a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of
30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the Holder of the Warrant
(who shall, with such notice, submit his Warrant for inspection by the Company), then the Holder of any Warrant may apply to the
Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s
cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing
under the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and
State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination
by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights,
immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder,
without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall
execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority,
powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall
make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming
to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

 

    	11

    	 

    

 

8.2.2       NOTICE
OF SUCCESSOR WARRANT AGENT. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof
to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.

 

8.2.3       MERGER
OR CONSOLIDATION OF WARRANT AGENT. Any corporation into which the Warrant Agent may be merged, converted or with which it may
be consolidated or any corporation resulting from any merger, conversion or consolidation to which the Warrant Agent shall be a
party shall be the successor Warrant Agent under this Agreement without any further act.

 

8.3          FEES
AND EXPENSES OF WARRANT AGENT.

 

8.3.1       REMUNERATION.
The Company agrees to pay the Warrant Agent the remuneration set forth in that certain Fee Proposal delivered to the Company on
October __, 2014 for its services as such Warrant Agent hereunder and will reimburse the Warrant Agent upon demand for all expenditures
that the Warrant Agent may reasonably incur in the execution of its duties hereunder.

 

8.3.2       FURTHER
ASSURANCES. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged,
and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for
the carrying out or performing of the provisions of this Agreement.

 

8.4          LIABILITY
OF WARRANT AGENT.

 

8.4.1       RELIANCE
ON COMPANY STATEMENT. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it necessary
or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively
proved and established by a statement signed by the President or Chairman of the Board of the Company and delivered to the Warrant
Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions
of this Agreement.

 

8.4.2       INDEMNITY.
The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company
agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable
counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement except as a result of the Warrant
Agent’s gross negligence, willful misconduct, or bad faith.

 

8.4.3       EXCLUSIONS.
The Warrant Agent shall have no responsibility with respect to the validity or execution of any Warrant (except its countersignature
thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or
in any Warrant; nor shall it be responsible to make any adjustments required under the  provisions of Section 5 hereof
or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would
require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization
or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares
of Common Stock will when issued be valid and fully paid and nonassessable.

 

8.5          ACCEPTANCE
OF AGENCY. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the
terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised
and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares of the
Company’s Common Stock through the exercise of Warrants.

 

    	12

    	 

    

 

9.           MISCELLANEOUS PROVISIONS.

 

9.1          SUCCESSORS.
All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure
to the benefit of their respective successors and assigns.

 

9.2          NOTICES.
Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent to or on the Company shall
be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service
within five days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company
with the Warrant Agent) to the address set forth on the signature page of the Company. Any notice, statement or demand authorized
by this Agreement to be given or made by the Company to or on the Warrant Agent shall be sufficiently given when so delivered if
by hand or overnight delivery, if sent by certified mail or private courier service within five days after deposit of such notice,
postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with the Company) to the address set
forth on the signature page of the this Agreement, or if sent by electronic mail in portable document format (PDF) by 12:00 noon
Pacific Time on the day such notice, statement or demand is to be made.

 

9.3          APPLICABLE
LAW. This Agreement shall be construed and interpreted in accordance with the internal laws of the State of New York, without
giving effect to the conflict of laws principles thereof.

 

9.4          PERSONS
HAVING RIGHTS UNDER THIS AGREEMENT. Nothing in this Agreement expressed and nothing that may be implied from any of the provisions
hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto.
All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive
benefit of the parties hereto and their successors and assigns.

 

9.5          EXAMINATION
OF THE WARRANT AGENT AGREEMENT. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant
Agent in the Borough of Brooklyn, City and State of New York, for inspection by the registered Holder of any Warrant. The Warrant
Agent may require any such Holder to submit his Warrant for inspection by it.

 

9.6          COUNTERPARTS.
This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to
be an original, and all such counterparts shall together constitute but one and the same instrument.

 

9.7          EFFECT
OF HEADINGS. The Section headings herein are for convenience only and are not part of this Agreement and shall not affect the
interpretation thereof.

 

9.8          AMENDMENTS.
This Agreement may be amended by the parties hereto without the consent of any registered Holder for the purpose of curing any
ambiguity, or of curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions
with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties
deem shall not adversely affect the interest of the registered Holders. All modifications or amendments that adversely affect the
interest of the registered Holders, including any amendment to increase the Exercise Price or shorten the Exercise Period, shall
require the written consent of each of the Company and the registered Holders of the Warrants. Notwithstanding the foregoing, the
Company may lower the Exercise Price or extend the duration of the Exercise Period in accordance with Sections 4.1 and 4.2, respectively,
without such consent.

 

9.9          SEVERABILITY.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

    	13

    	 

    

 

[REMAINDER OF PAGE DELIBERATELY LEFT BLANK]

 

    	14

    	 

    

 

IN WITNESS WHEREOF, this Agreement has been duly executed by
the parties hereto as of the day and year first above written.

 

	 	PALATIN TECHNOLOGIES, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

Address for Notice:

Palatin Technologies, Inc.

4B Cedar Brook Drive

Cranbury, New Jersey 08512

Attn: President

	 	AMERICAN STOCK TRANSFER &
	 	TRUST COMPANY, LLC
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

Address for Notice:

American Stock Transfer & Trust Company LLC

6201 15th Avenue, 2nd Floor

Brooklyn, NY 11219

Attn: Corporate Trust Department

 

    	15

    	 

    

 

EXHIBIT A

 

COMMON STOCK PURCHASE WARRANT

 

PALATIN TECHNOLOGIES, INC.

 

CUSIP NO. ________________

 

	No.	 	 
	 	 	 
	Warrant Shares:	 	Initial Exercise Date: October __, 2014

 

THIS COMMON STOCK PURCHASE WARRANT (this
“Warrant”) certifies that, for value received,                     
or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the Initial Exercise Date, as listed above, and on or prior to the close
of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date ”) but not
thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the “Company”),
up to              shares (as subject to adjustment hereunder,
the “Warrant Shares”) of the Company’s common stock, par value $0.01 per share (“ Common Stock
”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b). This Warrant is issued or to be issued pursuant to a Warrant Agent Agreement, dated October ___, 2014 (the “Warrant
Agreement”), duly executed and delivered by the Company to American Stock Transfer & Trust Company, LLC, as warrant
agent (the “Warrant Agent,” which term includes any successor warrant agent under the Warrant Agreement), which
Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description
of the rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and the Holders.

 

Section 1 .              Definitions.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated in this Section 1:

 

“Affiliate” means any
Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board of Directors”
means the board of directors of the Company.

 

“Business Day” means
any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Commission” means the
United States Securities and Exchange Commission.

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Liens” means a lien,
charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

    	1

    	 

    

 

“Person” means an individual
or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint
stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding” means an
action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.

 

“Rule 144” means Rule
144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such
Rule.

 

“Securities Act” means
the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading Day” means a
day on which the Common Stock is traded on a Trading Market.

 

“Trading Market” means
any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE MKT LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange
or the OTC Bulletin Board (or any successors to any of the foregoing.

 

“Transfer Agent” means
American Stock Transfer & Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 6201
15th Avenue, Brooklyn, New York 11219 and a facsimile number of 718-765-8726, and any successor transfer agent of the
Company.

 

“VWAP” means, for any
date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted
on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTC Bulletin Board is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board,
(c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock
are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

Section 2.              Exercise.

 

a) Exercise of Warrant. Exercise of the
purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company or the
Warrant Agent) of a duly executed e-mailed copy of the Notice of Exercise form annexed hereto, subject to the Company’s confirmation
of receipt of the e-mail. Within three (3) Trading Days following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer of immediately available
funds, or pursuant to the cashless exercise procedure specified in Section 2(c) below, if such cashless exercise procedure
is available and is specified in the applicable Notice of Exercise. Subject to Section 2(d)(ii), the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder
and this Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three (3) Trading Days after the date the final Notice of Exercise is delivered to the Company. Partial exercises of
this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect
of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one (1) Business Day after
receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    	2

    	 

    

 

b)              Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $[___], subject to adjustment hereunder
(the “Exercise Price”).

 

c)              Cashless
Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised,
in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive
that number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

	 	(A)  =	the VWAP on the Trading Day immediately preceding the date on which the Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable Notice of Exercise;	 
	 	(B)  =	the Exercise Price of this Warrant, as adjusted hereunder; and	 
	 	(X)  =	the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

d)           Mechanics
of Exercise.

 

i.              Delivery
of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder
by crediting the account of the Holder’s prime broker with The Depository Trust Company through its system (“DWAC”)
system if the Company is then a participant in such system and either (A) there is an effective registration statement permitting
the issuance of the Warrant Shares to the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise
by physical delivery to the address specified by the Holder in the Notice of Exercise, in each case by the date that is three (3) Trading
Days after the latest of (A) the delivery to the Company of the Notice of Exercise and receipt of the DWAC request from the
Holder’s prime broker (if applicable), (B) surrender of this Warrant (if required) and (C) payment of the aggregate
Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the “ Warrant Share Delivery
Date ”). The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to
be named therein shall be deemed to have become the holder of record of such shares for all purposes, as of the date this Warrant
has been properly exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all
taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having
been paid.

 

ii.              Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of
the Holder and upon surrender of this Warrant, at the time of delivery of the certificate or certificates representing Warrant
Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called
for by this Warrant, which new Warrant shall in all other respects be identical to this Warrant.

 

    	3

    	 

    

 

iii.              Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit either to the Holder’s prime broker the Warrant
Shares or to the Holder a certificate or the certificates representing the Warrant Shares, as applicable pursuant to Section 2(d)(i)
hereof by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.              Compensation
for Buy-In on Failure to Timely Deliver Shares Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to instruct the Transfer Agent to transmit to the Holder’s prime broker the Warrant Shares, or to the
Holder a certificate or the certificates representing the Warrant Shares pursuant to an exercise on or before the Warrant Share
Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder
of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company
shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at
issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the
option of the Holder, either reinstate the portion of this Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common
Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example,
if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise
of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Company shall only be obligated
to pay the Holder pursuant to this Section 2(d)(iv) upon the Holder’s delivery to the Company of a written notice indicating
the amounts payable to the Holder in respect of the Buy-In and evidence of the amount of such loss. Nothing herein shall limit
the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates
representing shares of Common Stock upon exercise of this Warrant as required pursuant to the terms hereof.

 

v.               No Fractional Shares or Scrip. No fractional
shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share
which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to
the next whole share.

 

vi.              Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it
for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any
Notice of Exercise.

 

    	4

    	 

    

 

vii.            Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

e)              Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and the Holder shall not have the right
to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates,
and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates) would beneficially own
in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable
upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of
any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation
on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except
as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the
Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of
which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall
have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant
that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, the Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the
written or oral request of the Holder, the Company shall within two (2) Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 9.98% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon exercise of this Warrant. Upon delivery of a written notice to the Company,
the Holder may from time to time increase (with such increase not effective until the sixty-first (61st) day after delivery
of such notice) or decrease the Beneficial Ownership Limitation to any other percentage not in excess of 19.99% (except that such
increased percentage may exceed 19.99% in the event that (x) the Company obtains the approval of its stockholders as required by
the applicable rules of the Trading Market on which the Common Stock is traded for issuances of shares of Common Stock in excess
of such amount or (y) the Company is not subject to rules of a Trading Market limiting issuances of shares of Common Stock in excess
of such amount) as specified in such notice; provided that (i) any such increase in the Beneficial Ownership Limitation will not
be effective until the sixty-first (61st) day after such notice is delivered to the Company, and (ii) any such increase
or decrease will apply only to the Holder and its affiliates and not to any other holder of this Warrant that is not an affiliate
of such Holder. For purposes of clarity, the shares of Common Stock underlying this Warrant in excess of the Beneficial Ownership
Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or
Rule 16a-1(a)(1) of the Exchange Act. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to the extent necessary to correct this paragraph or any portion
of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section
2(e) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation as contained
in this paragraph may not be waived and shall apply to a successor holder of this Warrant.

 

    	5

    	 

    

 

Section 3.              Certain
Adjustments.

 

a)              Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a dividend or otherwise
makes a distribution or distributions, in each case payable in shares of its Common Stock, to all holders of Common Stock (and
not to the Holders) (excluding, for avoidance of doubt, any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, or (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then in each case the Exercise
Price shall be multiplied by a fraction, of which the numerator shall be the number of shares of Common Stock (excluding treasury
shares, if any) outstanding at 5:00 p.m. (New York City time) on the Trading Day immediately before such event, and of which the
denominator shall be the number of shares of Common Stock that would be outstanding immediately after, and solely as a result of,
such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate
Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately prior to 9:00 a.m. (New York city time) on the Ex-Dividend Date for such dividend or distribution or the effective
date of such subdivision or combination, as the case may be. “ Ex-Dividend Date ” means, when used with respect
to any dividend, distribution or issuance, the first date on which the share of Common Stock trade on the Trading Market, regular
way, without the right to receive the relevant dividend, distribution or issuance.

 

b)              [INTENTIONALLY
DELETED]

 

c)              Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the
record holders of any class of shares of Common Stock (the “ Purchase Rights ”), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase
Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation).

 

    	6

    	 

    

 

d)              Pro
Rata Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common
Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants
to subscribe for or purchase any security other than the Common Stock (which shall be subject to Section 3(c)), then in each
such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date
fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the
VWAP determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the
then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable
to one outstanding share of the Common Stock as determined by the Board of Directors in good faith. In each case the adjustments
shall be described in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or
such subscription rights applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution
is made and shall become effective immediately after the record date mentioned above.

 

e)              Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person and the Company is not
the surviving corporation, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged
for other securities, cash or property, or (iv) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group of Persons acquires
more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other
Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the
exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction that is (1) an all cash transaction,
(2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act, or (3) a Fundamental Transaction
involving a person or entity not traded on a national securities exchange, including, but not limited to, the NYSE MKT LLC, the
Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market, the Company or any Successor Entity (as defined
below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation
of the Fundamental Transaction, purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black
Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction.
“Black Scholes Value” means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained
from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation
of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the average of 10, 20 and
30-day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater
of (i) the weighted average price of the Common Stock for the Trading Day immediately preceding the date of announcement of the
applicable  Fundamental Transaction, (ii) the weighted average price of the Common Stock for the Trading Day immediately following
the date of announcement of the applicable  Fundamental Transaction and (iii) the weighted average price of the Common Stock
for the Trading Day immediately preceding the date of consummation of the applicable  Fundamental Transaction, and (D) a
remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and
the Termination Date. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the
survivor (the “ Successor Entity ”) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number
of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such
Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant
and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

 

    	7

    	 

    

 

f)            Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case
may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)            Notice
to Holder.

 

i.              Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.

 

    	8

    	 

    

 

ii.              Notice
to Allow Exercise by Holder. If during the term in which this Warrant may be exercised by the Holder (A) the Company
shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a
special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to
all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class, (D) the
approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any
consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the
Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the
Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then,
in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register
of the Company, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously disclose such information
in compliance with applicable securities laws. The Holder shall remain entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth
herein.

 

Section 4. Transfer of Warrant.

 

a)              Transferability.
Subject to compliance with applicable securities laws, this Warrant and all rights hereunder are transferable, in whole and not
in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds
sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment,
the Company shall execute and deliver a new Warrant in the name of the assignee and this Warrant shall promptly be cancelled. This
Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.

 

b)              New
Warrants. This Warrant may be combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder
or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or Warrants to be combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall include reference to the initial issuance date set forth
on the first page of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto and the Warrant number.

 

c)              Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual written notice to the contrary.

 

Section 5.              Miscellaneous.

 

a)              No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b)             Delegation of Duties.
The Company may delegate the performance of any of its duties contemplated hereunder to the Warrant Agent pursuant to the terms
set forth in the Warrant Agreement.

 

    	9

    	 

    

 

c)              Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and
cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate
of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. Applicants for a replacement Warrant
under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable
charges as the Company may prescribe.

 

d)              Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

e)              No
Inconsistent Actions. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the
taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all
such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations,
exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company
to perform its obligations under this Warrant.

 

f)              Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in
accordance with the provisions of the Purchase Agreement.

 

g)              Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions
upon resale imposed by state and federal securities laws unless the Holder utilizes the cashless exercise provisions hereof.

 

h)              Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall
operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies. Without limiting any other
provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision
of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall
be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those
of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its
rights, powers or remedies hereunder.

 

i)              Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
to the registered Holder at the last address as it shall appear upon the Warrant Register of the Company.

 

j)              Limitation
of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for
the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.

 

    	10

    	 

    

 

k)              Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to seek specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

l)              Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.

 

m)             Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

n)              Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

o)              Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part
of this Warrant.

 

********************

 

(Signature Page Follows)

 

    	11

    	 

    

 

IN WITNESS WHEREOF, the undersigned have
caused this Warrant Certificate to be executed as of the date set forth below.

 

	 	PALATIN TECHNOLOGIES, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

	Dated:	 	 
	 	 	 
	Countersigned:	 

 

	 	 
	AMERICAN STOCK TRANSFER &	 
	TRUST COMPANY, LLC	 
	 	 	 
	By:	 	 
	 	Name:	 
	 	Title:	 

    	12

    	 

    

 

EXECUTION COPY

 

NOTICE OF EXERCISE

 

TO: PALATIN TECHNOLOGIES, INC.

 

(1)           The
undersigned hereby elects to purchase              Warrant Shares
of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together
with all applicable transfer taxes, if any.

 

(2)           Payment
shall take the form of (check applicable):

 

___ in lawful money of the United States;
or

 

___ the cancellation of such number of Warrant
Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the
maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(3)           Unless
the Warrant Shares will be delivered electronically via DWAC, please issue a certificate or certificates representing said Warrant
Shares in the name of the undersigned or in such other name as is specified below:

 

and deliver the physical certificate representing said Warrant
Shares to the following address:

 

                     
..

 

If the Warrant Shares will be delivered electronically via DWAC,
please issue them to the following account:

 

	 	o	Name of DTC Participant:                                                      
	 	 	 
	 	o	DTC Participant Number:                                                        
	 	 	 
	 	o	Name of Account at DTC Participant to be credited with the Warrant Shares:                                                      
	 	 	 
	 	o	Account Number at DTC Participant to be credited with the Warrant Shares:                                                      

 

    	13

    	 

    

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:

 

Signature of Authorized Signatory of Investing Entity:
__________________________________________

 

Name of Authorized Signatory: _______________________________________

 

Title of Authorized Signatory: ________________________________________

 

Date: ______________________

 

    	14

    	 

    

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, execute

 

this form and supply required information.

 

Do not use this form to exercise the Warrant.)

 

FOR VALUE RECEIVED, all of the shares of the foregoing Warrant
and all rights evidenced thereby are hereby assigned to

 

                         
                                         
                                         
                     
whose address is

 

                                 
                                         
                                         
                                         
     .

 

Dated:                             
,                  

 

	 	Holder’s Signature:	 
	 	 	 
	 	 	 
	 	Holder’s Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

Signature Guaranteed:                                          
                                         
                          

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Warrant.

 

    	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]